Safety and adherence to self‐administered intravaginal 5‐fluorouracil cream following cervical intraepithelial neoplasia ( <scp>CIN</scp> ) 2/3 treatment among <scp>HIV</scp> ‐positive women in Kenya: A phase 1 clinical trial
Self-administered 5FU following CIN2/3 treatment among WLWH in Kisumu, Kenya, was safe, tolerable, and associated with high adherence. Randomized trials are needed to investigate whether adjuvant 5FU can improve treatment outcomes or serve as primary cervical precancer treatment in sub-Saharan Africa. A self-administered therapy may be transformative in increasing access to treatment and, hence, secondary prevention of cervical cancer.
Authors
- Jennifer H. Tang (ORCID: https://orcid.org/0000-0003-4238-2791)
- Cirilus Ogollah
- Jackton Omoto
- Lisa Rahangdale (ORCID: https://orcid.org/0000-0002-4444-7969)
- Elizabeth A. Bukusi (ORCID: https://orcid.org/0000-0002-2031-2808)
- Chemtai Mungo (ORCID: https://orcid.org/0000-0002-3655-4721)
- Mercy Rop
- Antony Owaya
- Gershon Rota
Institutions
- University of North Carolina at Chapel Hill (US)
- Maseno University (KE)
- Kenya Medical Research Institute (KE)
- UNC Lineberger Comprehensive Cancer Center
Publication Details
- Journal
- International Journal of Gynecology & Obstetrics
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1002/ijgo.16093
- Citations
- 3
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Global Fund for Women
- Pelotonia
- Bausch Health
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development